← Back to Search

Other

Amantadine for Cognitive Impairment in Post-COVID Syndrome (AmantadineLC Trial)

Phase 1

Recruiting

Research Sponsored by Ohio State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Is not currently taking a medication with adverse interactions with amantadine

18 years of age and above at the signing of informed consent

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 months

Awards & highlights

AmantadineLC Trial Summary

This trial will study how amantadine affects thinking in people with Long COVID, and if tests can tell who it helps most.

Who is the study for?

This trial is for adults over 18 who've had COVID-19 and are now experiencing cognitive issues due to Long COVID. They must not be pregnant, breastfeeding, or at risk of pregnancy without birth control. Participants should not have a history of seizures, heart problems, certain mental health conditions, or be on conflicting medications.Check my eligibility

What is being tested?

The study tests whether amantadine can improve brain function in people with Long COVID. It involves taking the drug and undergoing cognitive assessments while avoiding alcohol use during the study period.See study design

What are the potential side effects?

Amantadine may cause side effects such as nausea, dizziness or lightheadedness when standing up quickly (orthostatic hypotension), dry mouth, difficulty concentrating, and potential mood changes.

AmantadineLC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am not on medication that interacts badly with amantadine.

Select...

I am 18 years old or older.

AmantadineLC Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Improvement in cognitive symptoms

Improvement on objective cognitive testing

Secondary outcome measures

Medication tolerability

Mood symptoms

Side effects data

From 2013 Phase 4 trial • 68 Patients • NCT01071395

11%

Dry mouth

100%

80%

60%

40%

20%

Study treatment Arm

Placebo

Amantadine

AmantadineLC Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: AmantadineExperimental Treatment1 Intervention

Subjects will be treated with amantadine.

Group II: PlaceboPlacebo Group1 Intervention

Subjected received placebo identical to amantadine in appearance.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Amantadine

2010

Completed Phase 4

~740

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Ohio State UniversityLead Sponsor

830 Previous Clinical Trials

505,560 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Amantadine obtained the Food and Drug Administration's seal of approval?

"Clinical data available is limited in regards to Amantadine's safety and efficacy, so it has been given a score of 1."

Answered by AI

Are any fresh participants being accepted for this trial?

"This experiment is not currently recruiting participants, but was last updated on September 22nd 2023. However, there are 1425 other clinical trials actively searching for volunteers at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Amantadine Therapy for Cognitive Impairment in Long COVID

Andrew Schamess 2023. "Amantadine Therapy for Cognitive Impairment in Long COVID". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06055244.

All > Survivor Corps